ATE339451T1 - Antagonistische monoklonale antikörper gegen menschliches cd40 - Google Patents

Antagonistische monoklonale antikörper gegen menschliches cd40

Info

Publication number
ATE339451T1
ATE339451T1 AT99104709T AT99104709T ATE339451T1 AT E339451 T1 ATE339451 T1 AT E339451T1 AT 99104709 T AT99104709 T AT 99104709T AT 99104709 T AT99104709 T AT 99104709T AT E339451 T1 ATE339451 T1 AT E339451T1
Authority
AT
Austria
Prior art keywords
antibodies
antibody
cells
treat
insect cells
Prior art date
Application number
AT99104709T
Other languages
English (en)
Inventor
Boer Mark De
Leah B Conroy
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27360277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE339451(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/910,222 external-priority patent/US5397703A/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE339451T1 publication Critical patent/ATE339451T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99104709T 1992-07-09 1993-07-08 Antagonistische monoklonale antikörper gegen menschliches cd40 ATE339451T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/910,222 US5397703A (en) 1992-07-09 1992-07-09 Method for generation of antibodies to cell surface molecules
US08/015,147 US5869050A (en) 1992-07-09 1993-02-09 Methods of blocking T-cell activation using anti-B7 monoclonal antibodies
US08/070,158 US5677165A (en) 1992-07-09 1993-05-28 Anti-CD40 monoclonal antibodies capable of blocking B-cell activation

Publications (1)

Publication Number Publication Date
ATE339451T1 true ATE339451T1 (de) 2006-10-15

Family

ID=27360277

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93917032T ATE258595T1 (de) 1992-07-09 1993-07-08 Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle
AT99104709T ATE339451T1 (de) 1992-07-09 1993-07-08 Antagonistische monoklonale antikörper gegen menschliches cd40

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93917032T ATE258595T1 (de) 1992-07-09 1993-07-08 Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle

Country Status (5)

Country Link
EP (3) EP0651797B1 (de)
AT (2) ATE258595T1 (de)
DE (2) DE69334064T2 (de)
DK (1) DK0945465T3 (de)
ES (1) ES2273452T3 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
CN1450912A (zh) * 2000-04-19 2003-10-22 泰诺士公司 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
AU2001259215A1 (en) * 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2002028905A2 (en) * 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
EP2009027B1 (de) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Monoklonaler Antikörper gegen CD40
DE10132308A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Kombinationspräparat zur Therapie von immunologischen Erkrankungen
WO2003028809A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Methods of therapy for b-cell malignancies
WO2003029296A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
JP2008509080A (ja) * 2004-04-27 2008-03-27 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法
EP1854810A1 (de) 2006-05-09 2007-11-14 PanGenetics B.V. De-immunisierter und antagonister monoclonaler Antikörper gegen CD40, der aus der ch5D12 Antikörper abgeleitet ist
WO2017059243A2 (en) * 2015-09-30 2017-04-06 Janssen Biotech, Inc. Agonistic antibodies specifically binding human cd40 and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000092A1 (en) * 1990-07-02 1992-01-09 Bristol-Myers Squibb Company Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
ATE258595T1 (de) 2004-02-15
EP0651797A1 (de) 1995-05-10
ES2273452T3 (es) 2007-05-01
EP0945465B1 (de) 2006-09-13
DE69334064D1 (de) 2006-10-26
EP0651797B1 (de) 2004-01-28
DE69333403D1 (de) 2004-03-04
DK0945465T3 (da) 2007-01-15
DE69334064T2 (de) 2007-05-24
EP0945465A1 (de) 1999-09-29
EP1834671A3 (de) 2013-05-22
DE69333403T2 (de) 2004-11-11
EP1834671A2 (de) 2007-09-19

Similar Documents

Publication Publication Date Title
WO1994001547A3 (en) A method for generation of antibodies to cell surface molecules
ATE339451T1 (de) Antagonistische monoklonale antikörper gegen menschliches cd40
Warner et al. Bone marrow graft rejection as a function of antibody-directed natural killer cells.
DE69128253T2 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
MX9201016A (es) Anticuerpos monoclonales humanizados y quimericos
CN1822857A (zh) 去免疫原性抗cd3抗体
EP0722463A4 (de) Verfahren und zusammensetzung für die modulation der wirtsimmunantwort auf allergene
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
CA2137638A1 (en) Anti Gangliosides Monoclonal Antibodies and Their Use in the Specific Active Immunotherapy of Malignant Tumors
JPH10505325A (ja) 治療剤としてのｔ細胞に対する抗体
CN1137726C (zh) 延长体液免疫抑制的方法
Murphy et al. CD40 stimulation promotes human secondary immunoglobulin responses in HuPBL-SCID chimeras
EP0765344A1 (de) Inhibierung von menschlichen xenogenen oder allogenen antikoerpern zur reduzierung der xenotransplantat- oder allotransplantatabstossung in menschlichen empfaengern
FI20095269A (fi) Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli
Dennert et al. Induction of bone marrow allograft rejection and hybrid resistance in nonresponder recipients by antibody: is there evidence for a dual receptor interaction in acute marrow graft rejection?
PL314414A1 (en) Antiidiotypic antibodies capable to induce an immunological response in respect to the receptor of epidermis growth factor
Thierfelder et al. Immunosuppression by Fc region‐mismatched anti‐T cell antibody treatment
Kremmer et al. Induction and suppression of anti-antibodies to syngeneic T cell-binding antibodies in mice
DE69020914T2 (de) Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.
EP0370090A4 (en) Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens
Else et al. Antibody isotype responses to Trichuris infection in humanized SCID mice
Mysliwietz et al. Long‐lasting unresponsiveness to polyclonal T cell‐binding immunoglobulins
Mateo et al. A different method for obtaining an engineered murine antibody, that recognizes epidermal growth factor receptor, with reduced immunogenicity
STRoNG et al. Anti-idiotype antibody in the primate
De Boer et al. Method for generation of antibodies to cell surface molecules

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0945465

Country of ref document: EP